Cenderitide_Dosage, benefits & legal status
Also known as CD-NP, chimeric natriuretic peptide, cenderitide acetate
A designed chimera rather than a copy of anything the body makes. The engineering is the interesting part.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is Cenderitide?
Plain language first. The technical label stays, but it never stands alone.Overview
Every other natriuretic drug is a copy of a natural hormone. This one was built from parts. The CNP half brings the receptor that does not drop blood pressure much, and the snake venom tail brings activity at the receptor that unloads the heart. It reached small human studies in heart failure and was never approved.
Cenderitide is a 37-residue chimeric peptide. Its first 22 residues are CNP, the C-type natriuretic peptide, and the remaining 15 are the C-terminal tail of Dendroaspis natriuretic peptide, found in green mamba venom. The design intent was to activate both NPR-B, the receptor CNP uses, and NPR-A, the one ANP and BNP use, while causing less of the blood pressure drop that limits the other drugs in this family.
What it's used for
Nothing outside research. It was an investigational peptide for heart failure and kidney protection, studied in small human trials.
How does Cenderitide work?
What it does in the body, and where.The natriuretic family splits across two receptors. NPR-A, used by ANP and BNP, unloads the heart but drops blood pressure. NPR-B, used by CNP, does far less to blood pressure. Cenderitide was built to reach both.
- 01The CNP halfThe first 22 residues are CNP exactly as the body makes it, including the ring closed between cysteines 6 and 22. That part brings NPR-B activity. The site's navepegritide card carries the same ring inside a longer 38-residue version of CNP.
- 02The venom tailThe last 15 residues come from Dendroaspis natriuretic peptide, isolated from green mamba venom. That tail is what adds activity at NPR-A, the receptor the heart failure drugs use.
- 03Why anyone would do thisNesiritide and ularitide both work through NPR-A, both lower blood pressure, and both failed to help patients in large trials. The argument for a chimera is that hitting two receptors at once might unload the heart and protect the kidney without the pressure drop. That argument has never been tested in a trial large enough to answer it.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
What the sequence shows
none- lab-analysisThe first 22 residues match the C-terminal 22 residues of the CNP sequence on this site's navepegritide card exactly, with cysteines in the same two positions.
- lab-analysisThe remaining 15 residues, PSLRDPRPNAPSTSA, are the C-terminal 15 of the 38-residue Dendroaspis natriuretic peptide of the eastern green mamba, UniProt P28374. The tail is verified against that record rather than merely attributed.
- No dataSo the molecule is a join, not a modified copy of one hormone. That is unusual on this site: almost every other peptide here is either a natural sequence or a natural sequence with substitutions.
In people
Investigational- Human trialBoth registered trials were small and both ran the drug as a continuous infusion under the skin through a wearable Insulet pump. NCT02359227 was an open-label phase 2 in 14 adults with stable chronic heart failure, running January to April 2015. NCT02603614 was a randomized, double-blind, placebo-controlled crossover phase 1/2 in 8 adults who also had moderate kidney impairment, running December 2015 to March 2016. Both completed. Neither posted results.
- human-earlyBefore those, a company release in 2007 reported a four-hour infusion in 22 healthy volunteers at 10, 17.5 and 25 nanograms per kilogram per minute against placebo. Plasma cyclic GMP rose by an average of 202, 378 and 691 percent across the three rates, urine flow and sodium excretion rose, and mean arterial pressure did not fall. That is a sponsor press release rather than a peer-reviewed paper, and the numbers are average changes from baseline.
- Human trialA peer-reviewed human study exists, Kawakami and colleagues in Clinical Pharmacology and Therapeutics, 2018, titled as an evaluation of safety, tolerability and cyclic GMP activating properties in stable chronic heart failure. We did not read its full text, so no number from it is quoted here.
- No dataThe largest of these was 22 people, so it never reached a trial able to test survival or hospitalization, the endpoints that defeated nesiritide and ularitide. Capricor returned the rights to Mayo in February 2017 and nothing has been registered since.
Cenderitide is described as a dual-receptor natriuretic peptide, and that is the design intent rather than a demonstrated result: the human studies measured cyclic GMP, the second messenger both receptors share, so they show the molecule is active in people without separating NPR-A from NPR-B, and the two-receptor split rests on cell work. It is sometimes called a CNP analog, and that understates it, since 15 of its 37 residues come from a snake venom peptide instead. CD-NP and cenderitide are the same molecule.
The published record
Papers and trials about Cenderitide
41 papers tagged human · 16 not reviews or lab · 2 clinical trial publications
12 registered trials · none with posted results
Furthest stage reached: Phase 2, completed, no results posted
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about Cenderitide
Evidence
Investigational
Category
Sexual and hormonal
Common vial
Varies
Half-life
Nothing read from a primary source
How much, and do you cycle it?
The range, and whether you take breaks.No established dose, not established. Not established No range
No dose or schedule has been established in people, and development has not progressed beyond small studies.
Nothing read from a primary sourceNo figure
No half-life figure is quoted because none was read from a primary source. The way it was given says the duration of action is short: every human study used a continuous infusion, four hours in the early work and a wearable pump running for days in both Capricor trials. Natural CNP itself clears within minutes.
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
Cenderitide has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Solubility, computed: 24% charged residues, 43% hydrophobic. Acid may help.
A first-pass rule from peptide manufacturers' guidance. It does not account for disulfide bridges, salt form or how the powder was dried, and it predicts what should be easy rather than what will happen in your vial.
Who should avoid it
- Any use outside a study: it is not approved anywhere and no product exists
- Anything sold under this name: the sequence is public, but a research powder is not a sterile medicine
Stop and get help
- Not applicable outside a study
Common effects
- Only partly characterized. The human studies were small and aimed at safety and cyclic GMP signaling, and none has posted results. Dizziness, fast heartbeat and lightheadedness on standing appeared at the highest rate tested in healthy volunteers
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is Cenderitide approved?
And where the numbers on this page come from.No. Cenderitide was never approved, and its development has ended. There is no legal route to obtain it as a medicine.
- Approval statusInvestigational
- RouteUnder the skin, or into a vein (in studies)
- Checked24 October 2026
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesFDA GSRS substance record, cenderitide (UNII 9NKZ9LYZ06)ClinicalTrials.gov, NCT02359227ClinicalTrials.gov, NCT02603614Kawakami and colleagues, Clinical Pharmacology and TherapeuticsNile Therapeutics press release, first human study of CD-NPCapricor Therapeutics Form 8-K, termination of the Mayo license
What has happened recently
Not approved anywhere, and development has stopped. Identity is settled: FDA substance record UNII 9NKZ9LYZ06, CAS 507289-11-4, with an acetate record at UNII 7SWB0S93AK carrying the same 37-residue sequence. The nonproprietary name is simply cenderitide; the numbers 9438 and XX-131 that circulate with it are its registry codes in the INN and USAN systems, not alternative names. Two registered trials exist, both sponsored by Capricor and both completed with no results posted: NCT02359227, an open-label phase 2 in 14 adults with stable chronic heart failure, and NCT02603614, a randomized, double-blind, placebo-controlled crossover phase 1/2 in 8 adults who also had moderate kidney impairment. In February 2017 Capricor told the Securities and Exchange Commission it was terminating its Mayo Clinic license covering natriuretic peptide receptor agonists, including cenderitide and the related CU-NP, and returning those rights so it could concentrate on cell and exosome work. Nothing has been registered since.
You can compare this against the whole library, or read how to check a seller.
What else is like Cenderitide?
Others in Sexual and hormonal, side by side.If you're weighing Cenderitide, it's worth reading PT-141 (Bremelanotide), Kisspeptin, and Gonadorelin (GnRH) in the same class.
A designed chimera rather than a copy of anything the body makes. The engineering is the interesting part.
- Dose
- No established dose
- How often
- Not established
An approved shot that boosts sexual desire through the brain.
- Dose
- 1.75 mg per dose
- How often
- As needed, before activity
A peptide that switches on natural sex-hormone signaling for libido and fertility.
- Dose
- 0.1 up to 0.2 mg per dose
- How often
- Daily in vendor protocols
A shot that keeps your own testosterone and fertility hormones going.
- Dose
- 0.1 up to 0.2 mg per dose (start low, increase slowly)
- How often
- 2-3x per week or more
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- FDA GSRS substance record, cenderitide (UNII 9NKZ9LYZ06)(2026)Protein record, 37 residues, one disulfide bond joining cysteines 6 and 22. INN registry number 9438, USAN code XX-131, CAS 507289-11-4, plus a separate acetate record at UNII 7SWB0S93AK with the same sequence.
- ClinicalTrials.gov, NCT02359227(2015)Capricor Inc., phase 2, completed, 14 participants actual, open-label single group, January to April 2, 2015. Continuous subcutaneous infusion through the Insulet Drug Delivery System: four 48-hour periods at 0.5, 1.0, 2.0 and 3.0 ng/kg/min across up to eight sequential days, in stable chronic heart failure. No results section.
- ClinicalTrials.gov, NCT02603614(2016)Capricor Inc., phase 1/phase 2, completed, 8 participants actual, randomized crossover with quadruple masking and two 7-day infusion periods, December 2015 to March 31, 2016. Continuous subcutaneous infusion through the Insulet system in chronic stable heart failure with moderate kidney impairment, GFR 30 to 60 mL/min, NYHA class II or higher. No results section.
- Kawakami and colleagues, Clinical Pharmacology and Therapeutics(2018)A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure. Volume 104, issue 3, pages 546 to 552, posted online January 11, 2018. Citation verified through Crossref; the full text was not read for this page.
- Nile Therapeutics press release, first human study of CD-NP(2007)Four-hour infusion in 22 healthy volunteers at placebo, 10, 17.5 or 25 ng/kg/min. Average change from baseline in plasma cyclic GMP 4, 202, 378 and 691 percent; urine flow 125, 53, 30 and 230 percent; sodium excretion 28, 138, 55 and 158 percent; mean arterial pressure -5, 6, -6 and -8 percent. Well tolerated with no serious adverse events; at the highest dose some subjects had transient dizziness, asymptomatic tachycardia and orthostatic hypotension. A sponsor release, not a peer-reviewed paper.
- Capricor Therapeutics Form 8-K, termination of the Mayo license(2017)Capricor gave notice of termination of the Amended and Restated Technology License Agreement with the Mayo Foundation, relinquishing all rights Mayo had licensed for CD-NP and CU-NP so it could focus on cell therapy and exosome programs. Filed February 16, 2017, event date February 13, with Mayo treating the agreement as ended as of February 14, 2017.
Beyond these, 73 records are indexed. Browse the records